newsfilter
← Latest News
GlobeNewswire·

Preclinical Data Show Annamycin Makes Pancreatic Cancer Responsive to Checkpoint Inhibitors, Opening a Combination Path with Immunotherapies

  • Moleculin Biotech announced new preclinical data showing Annamycin combined with PD-1 blockade extended survival in pancreatic cancer models beyond either agent alone.
  • Findings presented at the 6th Annual Marie Skłodowska-Curie Symposium indicate Annamycin converts immunologically "cold" pancreatic tumors into "hot" tumors by increasing infiltration of CD8+ & CD4+ T cells.
  • Pharmacokinetic studies reveal Annamycin achieves substantially higher & more sustained exposure in pancreatic tissue than doxorubicin, potentially explaining why topoisomerase II has been successfully targeted here.
  • Inhibiting CD8+ T cells in treated mice shortened survival, confirming these immune cells are functional contributors to Annamycin's antitumor activity rather than bystanders.
  • The data supports evaluating Annamycin in combination with approved PD-1 inhibitors for pancreatic cancer & other tumors limited by cold microenvironments.
  • Moleculin plans to sponsor an investigator-initiated clinical trial for Annamycin in pancreatic cancer in 2027.
  • CEO Walter Klemp noted Annamycin avoids cardiotoxicity & expands the drug's strategic value beyond its primary AML development program.
  • Dr. Priebe stated that while Annamycin reaches pancreatic tumors in sufficient concentrations, its ability to recruit functional T lymphocytes enables the combination with checkpoint blockade.
Company
Moleculin Biotech, Inc.
Keywords
Nasdaq:MBRX, Moleculin Biotech, Inc., Moleculin Biotech, Inc., Nasdaq: MBRX, Annamycin, Pancreatic Cancer, Immunotherapies, CD8+ T cells, immune system, treatment, MIRACLE